Dynamic Metabolic Parameters and Deauville Score on 18F-FDG PET/CT for Prognostic Assessment in Pediatric Burkitt Lymphoma

Résumé fourni par la source

Background/Objectives: 18F-FDG PET/CT is increasingly used in pediatric Burkitt lymphoma (BL) for staging and treatment response assessment, but data on quantitative prognostic markers remain limited. Methods: We retrospectively evaluated 33 children with pathologically confirmed BL who underwent baseline and end-of-treatment (EOT) 18F-FDG PET/CT between 2009 and 2024. SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured at baseline and EOT, and the Deauville score (DS) was assigned visually. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan–Meier method; receiver operating characteristic (ROC) analysis identified predictive thresholds. Results: Three-year and 5-year OS was 89.6%, and PFS was 90.1%. The percentage reduction in SUVmax from baseline to EOT (%ΔSUVmax) was the strongest predictor of survival (AUC = 0.94; optimal cutoff ≥ 73.6% reduction; sensitivity 100%, specificity 93%). Patients with an unfavorable EOT DS (4–5) had significantly lower OS than those with a favorable DS (1–3) (60.0% vs. 96.4%; log-rank p = 0.009). Baseline SUVmax, MTV, and TLG did not differ significantly by stage or splenic involvement. Given the small number of survival events (n = 3), the corresponding hazard ratios and confidence intervals should be regarded as exploratory and hypothesis-generating rather than definitive effect sizes. Conclusions: Dynamic metabolic response such as %ΔSUVmax and the EOT Deauville score are promising prognostic markers in pediatric BL. Given the small number of events, these findings warrant validation in larger, prospective cohorts.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.